Clene is continuing to work with U.S. regulators on its plans to seek accelerated approval of CNM-Au8 for the treatment of ...

Elanco (ELAN) stock in focus as Australia's Neurizon Therapeutics (PAAFF) enters into a licensing deal with the company for ...

Here’s a look at the life of renowned theoretical physicist, cosmologist, astronomer and mathematician, Stephen ...

Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased ...

While the broader market showed resilience to global geopolitical and economic pressures in June, the ASX 200 Health Care ...

Healx is an AI-powered and patient-inspired technology company, accelerating the discovery and development of rare disease treatments. ... This partnership combines the machine learning and ...

Patients with rare diseases are increasingly working to find and fund their own cures. But should they have to?

(NASDAQ:ARGX – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $720.00 price ...

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, has been in the headlines lately, owing in large ...

Exclusive Global Rights: Neurizon is granted exclusive global rights to Elanco’s data package and related intellectual property for monepantel to develop and commercialise NUZ-001 and its related ...